Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray

 Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions,
              Catalyst Pharmaceutical, MannKind, Amgen, Accuray

PR Newswire

CORAL SPRINGS, Florida, August 28, 2013

CORAL SPRINGS, Florida, August 28, 2013 /PRNewswire/ -- issues news updates for today's leading healthcare
companies: Bio-Solutions Corp. (OTCQB: BISU), Catalyst Pharmaceutical
Partners, Inc. (NASDAQ: CPRX), MannKind Corporation (NASDAQ: MNKD), Amgen
(NASDAQ: AMGN) and Accuray Incorporated (NASDAQ: ARAY).

Bio-Solutions Corp. (BISU): Bio-Solutions Corp. Announces National Direct
Response Marketing Campaign for Type2Defense™. Bio-Solutions today announces
a major step in their company's expansion process across the USA and
commitment to growth across America; as management celebrates the national
roll-out of a Direct Response Infomercial and Marketing Campaign for its
flagship product Type2Defense™. Type2Defense™ is a new dietary supplement
that has been developed to help support healthy blood glucose levels in
health-conscious individuals and those diagnosed with Type 2 Diabetes. The
Product's goal is to provide a safe and natural supplement that will assist in
the stabilization of healthy glucose levels along with providing strong

Bill Gallagher, CEO of Bio-Solutions Corp, said, "We are very excited to be
launching our unique product via direct response television in the USA, and
especially feeling confident that partnering with GVP Digital Media will give
us the edge for a successful campaign." Compared to other consumer groups,
diabetics are 1.6 times more likely to use alternative medicine either
exclusively or as a complement to traditional treatment. GVP Digital Media, a
leader in Direct Response, will begin to actively market Type2Defense through
their media contacts and network of brokers, sales consultants and agents. GVP
has already started test marketing Type2Defense in a National radio campaign.

To read the entire press release, please go to

Tuesday of this week, Bio-Solutions announced that the Company has initiated a
campaign on to help raise money for the benefit of Juvenile
Diabetes. is the premier destination on the internet for both
professional and amateur athletes. Monthly traffic to is in
excess of 14 million visitors per month and Bio-Solutions is confident that it
can reach athletes who have diabetes through and help them
reach their training potential by using the company's product, Type 2 Defense.
The Bio-Solutions Corp. page on will allow young athletes with
diabetes to interact with pro athletes with diabetes. This one on one
interaction with the pros will show young diabetics that diabetes is not an
obstacle to achieving greatness. The pro ranks are full of star athletes who
have made it to the top without letting diabetes get in their way. Go to for more details.

Catalyst Pharmaceutical Partners, Inc. (CPRX), a specialty pharmaceutical
company focused on the development and commercialization of novel prescription
drugs targeting rare (orphan) neuromuscular and neurological diseases, today
announced that its investigational product Firdapse(TM) (amifampridine
phosphate) has received "Breakthrough Therapy Designation" by the U.S. Food
and Drug Administration (FDA) for the symptomatic treatment of patients with
Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse(TM) is Catalyst's
investigational therapy that is being evaluated for the treatment of the
debilitating symptoms associated with LEMS, including muscle weakness.

MannKind Corporation (MNKD), a biopharmaceutical company, focuses on the
discovery, development, and commercialization of therapeutic products for
diabetes and cancer in the United States. Its lead product candidate includes
AFREZZA inhalation powder, an insulin that is in late-stage clinical
investigation for the treatment of adults with type 1 or type 2 diabetes for
the control of hyperglycemia. MNKD closed up 2.4% on above average trading
volume of 12.9Million shares on Tuesday August 27, 2013.

Amgen (AMGN) announced that it will present new data on omecamtiv mecarbil, a
small molecule cardiac myosin activator that is being studied for the
treatment of heart failure in collaboration with Cytokinetics. Amgen will also
present data on AMG 145, an investigational human monoclonal antibody that
inhibits PCSK9, a protein that reduces the liver's ability to remove
low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the
blood.1 Amgen will present the data at the upcoming ESC Congress 2013,
organized by the European Society of Cardiology, in Amsterdam.

Accuray Incorporated (ARAY) announced financial results for the fourth quarter
and fiscal year ended June 30, 2013. Non-GAAP results are provided to enhance
understanding of Accuray's ongoing core results of operations. Accuray
announced continued strength in new orders booked in the fourth quarter and
first patients treated in the United States with the new CyberKnife(r) M6(TM)
and TomoTherapy(r) H(TM) Series Systems as well as continued financial
discipline, operating expense control and decreased operating losses. Read
the full 4th Qtr results at

FinancialNewsMedia.comis leading provider of third party publishing &news
dissemination services. If you would like more information regarding our news
coverage solutions, please visithttp://www.financialnewsmedia.comfor more
details. Get an edge on the market with ourPremium News Alertsthat are FREE
for a limited time at Follow us on
Twitter: Sign up for our FREE SMS News alerts
delivered directly to your mobile phone by texting the word PRESS to
545454.(SMS alerts are free, however data rates may apply, check your
wireless plan for details.)

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:

Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1-954-345-0611

Press spacebar to pause and continue. Press esc to stop.